Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$271.77	$292.22	$262.21 ▼ $495.55	$36.28B	0.27	1.49 million shs	1.15 million shs
BIIB Biogen	$202.19	$199.78	$124.56 ▼ $219.72	$29.85B	0.16	1.36 million shs	596,261 shs
HALO Halozyme Therapeutics	$81.93	$73.08	$57.67 ▼ $82.99	$9.72B	0.84	1.69 million shs	1.66 million shs
INCY Incyte	$117.67	$106.82	$69.69 ▼ $119.60	$23.51B	0.76	1.49 million shs	1.21 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+1.61%	-6.73%	-11.91%	-17.35%
BIIB Biogen	0.00%	-1.84%	-6.41%	+11.91%	+53.73%
HALO Halozyme Therapeutics	0.00%	+5.29%	+9.30%	+27.04%	+40.68%
INCY Incyte	0.00%	+0.36%	+3.45%	+22.94%	+67.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$271.77	$292.22	$262.21 ▼ $495.55	$36.28B	0.27	1.49 million shs	1.15 million shs
BIIB Biogen	$202.19	$199.78	$124.56 ▼ $219.72	$29.85B	0.16	1.36 million shs	596,261 shs
HALO Halozyme Therapeutics	$81.93	$73.08	$57.67 ▼ $82.99	$9.72B	0.84	1.69 million shs	1.66 million shs
INCY Incyte	$117.67	$106.82	$69.69 ▼ $119.60	$23.51B	0.76	1.49 million shs	1.21 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+1.61%	-6.73%	-11.91%	-17.35%
BIIB Biogen	0.00%	-1.84%	-6.41%	+11.91%	+53.73%
HALO Halozyme Therapeutics	0.00%	+5.29%	+9.30%	+27.04%	+40.68%
INCY Incyte	0.00%	+0.36%	+3.45%	+22.94%	+67.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.85	Moderate Buy	$452.13	66.37% Upside
BIIB Biogen	2.53	Moderate Buy	$220.57	9.09% Upside
HALO Halozyme Therapeutics	2.54	Moderate Buy	$81.60	-0.40% Downside
INCY Incyte	2.36	Hold	$111.10	-5.58% Downside

Current Analyst Ratings Breakdown

Latest HALO, ALNY, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$103.00 ➝ $104.00
7/23/2026	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$105.00 ➝ $110.00
7/22/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$420.00 ➝ $400.00
7/21/2026	HALO Halozyme Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	BIIB Biogen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $280.00
7/21/2026	BIIB Biogen	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$217.00 ➝ $215.00
7/21/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
7/21/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
7/15/2026	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
7/14/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/14/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	9.77	$2.80 per share	97.20	$5.97 per share	45.52
BIIB Biogen	$9.89B	3.02	$22.64 per share	8.93	$124.45 per share	1.62
HALO Halozyme Therapeutics	$1.40B	6.96	$4.77 per share	17.17	$0.42 per share	195.07
INCY Incyte	$5.14B	4.57	$6.18 per share	19.04	$26.32 per share	4.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$3.66	74.25	26.33	N/A	11.72%	85.76%	10.32%	7/30/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	21.69	12.23	N/A	13.81%	12.83%	8.01%	7/29/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$2.78	29.47	8.92	0.34	23.13%	187.91%	21.92%	8/6/2026 (Estimated)
INCY Incyte	$1.29B	$7.08	16.62	15.07	1.06	26.71%	26.66%	19.77%	7/28/2026 (Estimated)

Latest HALO, ALNY, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.82	N/A	N/A	N/A	$402.28 million	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	N/A	N/A	N/A	$1.32 billion	N/A
7/29/2026	Q2 2026	BIIB Biogen	$3.02	N/A	N/A	N/A	$2.46 billion	N/A
7/28/2026	Q2 2026	INCY Incyte	$2.15	N/A	N/A	N/A	$1.49 billion	N/A
5/11/2026	Q1 2026	HALO Halozyme Therapeutics	$1.54	$1.60	+$0.06	$1.22	$358.60 million	$376.71 million
4/30/2026	Q1 2026	ALNY Alnylam Pharmaceuticals	$0.8720	$1.99	+$1.1180	$1.51	$1.12 billion	$1.17 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion
4/28/2026	Q1 2026	INCY Incyte	$1.38	$1.81	+$0.43	$1.47	$1.22 billion	$1.27 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
BIIB Biogen	0.34	3.06	2.41
HALO Halozyme Therapeutics	8.81	2.76	2.33
INCY Incyte	0.01	3.68	3.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
HALO Halozyme Therapeutics	97.79%
INCY Incyte	96.97%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
HALO Halozyme Therapeutics	2.50%
INCY Incyte	16.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.51 million	132.37 million	Optionable
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
HALO Halozyme Therapeutics	390	118.61 million	115.65 million	Optionable
INCY Incyte	2,844	199.78 million	167.42 million	Optionable

HALO, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

Incyte Corporation $INCY Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

38 minutes ago | marketbeat.com

Dimensional Fund Advisors LP Boosts Stock Holdings in Incyte Corporation $INCY

July 26 at 3:36 AM | marketbeat.com

Contrasting Apollomics (NASDAQ:APLM) and Incyte (NASDAQ:INCY)

July 26 at 2:58 AM | americanbankingnews.com

Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics

July 25 at 12:50 AM | finance.yahoo.com

Renaissance Technologies LLC Cuts Stock Position in Incyte Corporation $INCY

July 25 at 6:00 AM | marketbeat.com

Sei Investments Co. Has $67.25 Million Stake in Incyte Corporation $INCY

July 25 at 5:20 AM | marketbeat.com

KBC Group NV Lowers Position in Incyte Corporation $INCY

July 25 at 5:03 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Trims Stock Holdings in Incyte Corporation $INCY

July 25 at 3:14 AM | marketbeat.com

Incyte (NASDAQ:INCY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

July 25 at 2:12 AM | americanbankingnews.com

Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?

July 24 at 11:41 AM | zacks.com

Inceptionr LLC Takes $1.29 Million Position in Incyte Corporation $INCY

July 24 at 6:11 AM | marketbeat.com

Sanctuary Advisors LLC Sells 15,868 Shares of Incyte Corporation $INCY

July 24 at 4:35 AM | marketbeat.com

First Trust Advisors LP Acquires 224,206 Shares of Incyte Corporation $INCY

July 24 at 3:52 AM | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price

July 23, 2026 | marketbeat.com

Incyte Corporation $INCY Shares Acquired by Swiss National Bank

July 23, 2026 | marketbeat.com

Incyte Corporation $INCY Shares Purchased by Assetmark Inc.

July 23, 2026 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Incyte (NASDAQ:INCY)

July 23, 2026 | americanbankingnews.com

Incyte Corporation $INCY Shares Sold by Amova Asset Management Americas Inc.

July 22, 2026 | marketbeat.com

Incyte: Halozyme Collaboration Improves INCA033989 Delivery but Dose Requirements Keep Rating at Hold

July 21, 2026 | tipranks.com

Incyte: ENHANZE Licensing Bolsters INCA033989 Outlook as Buy Rating and $140 Price Target Are Reiterated

July 21, 2026 | tipranks.com

HALO Inks Deal With INCY to Support Cancer Therapy Development

July 21, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HALO, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$271.77 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$270.93 -0.84 (-0.31%)

As of 07/24/2026 07:34 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$202.19 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$201.20 -1.00 (-0.49%)

As of 07/24/2026 07:34 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics NASDAQ:HALO

$81.93 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$81.50 -0.43 (-0.52%)

As of 07/24/2026 07:34 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Incyte NASDAQ:INCY

$117.67 0.00 (0.00%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$117.00 -0.67 (-0.57%)

As of 07/24/2026 07:34 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, ALNY, BIIB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, ALNY, BIIB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Incyte NASDAQ:INCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, ALNY, BIIB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, ALNY, BIIB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Incyte NASDAQ:INCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools